Although the majority of pre-clinical and clinical results are from prostate cancer, c-Met inhibitors have been tested on other bone metastatic cancers, such as breast cancer, and showed a similar clinically efficacy [38]. The gene discussed is MET; the disease is prostate carcinoma.